This observational study is a large-scale, prospective, and multi-institutional observational study. Patients from 19 to 75 years of age, will take a self-assessment (PRO) during the study period before and after administration of Pexuclue tablet.
Data will be collected based on patient's medical records from daily visit. Enrolled subjects will take a Patient Reported Outcome (PRO) survey including Quality of life evaluation (GERD-HRQL) and self-awareness symptom (RDQ). The survey will be done twice (before and after the administration of Fexuclue tablet) electronically through an application (e-PRO).
Study Type
OBSERVATIONAL
Enrollment
10,067
Fexuclue Tablet 40mg
Jeonbuk National University Hospital
Jeonju, South Korea
Average score change in RDQ
Average score change in RDQ at least 2 weeks (up to 8 weeks) compared to baseline
Time frame: At least 2 weeks (up to 8 weeks)
changes in average score of the individual symptoms (reflux, heartburn, indigestion)
changes in average score of the individual symptoms (reflux, heartburn, indigestion) at least 2 weeks(up to 8 weeks) from baseline (0\~5)
Time frame: At least 2 weeks (up to 8 weeks)
RDQ validity rate
RDQ validity rate at least 2 weeks(up to 8 weeks) from baseline
Time frame: At least 2 weeks (up to 8 weeks)
Overall improvement evaluated by the subjects
Overall improvement result (scale 1\~5, Fully recovered/Much improvement/Moderate improvement/Unchanged/Aggravated) evaluated by the subjects at least 2 weeks(up to 8 weeks) from baseline
Time frame: At least 2 weeks (up to 8 weeks)
Overall improvement evaluated by the researchers
Overall improvement (scale 1\~5, Fully recovered/Much improvement/Moderate improvement/Unchanged/Aggravated) evaluated by the researchers at least 2 weeks(up to 8 weeks) from baseline
Time frame: At least 2 weeks (up to 8 weeks)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.